The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback